DCB Open Innovation Challenge 2024: Meet our Top 6!

Jorge Bondia (ES): AMIC Health – A digital ecosystem to educate children with type 1 diabetes through safe experimentation with gamified diabetes simulators

“AMIC Health is a digital ecosystem for the healthcare professional to educate children with type 1 diabetes through safe experimentation with gamified diabetes simulators and quantify effectiveness.”

Christine Brännvall (SE) : Beep Insights – Calculating insulin resistance based on level of physical activity

“The Beep app feature uses lactate measurement to estimate insulin resistance in relation to physical activity, CGM data, food  intake and sleep. Beep has built the world’s first in-app lactate step testing feature where both the test and the results are easily managed with a lactate testing device and analysed for you, without the need of any administration.”

Frédérik Plourde (CH) : Neuria – Evidence-based Neurocognitive Digital Therapeutics to restore healthy consumption behaviors without awareness

“Neuria’s gamified solution offers an evidence-based neurocognitive digital therapeutic that restores healthy consumption behaviors without awareness. Tested in 500+ individuals, it leverages brain plasticity and reduces cravings by 20%, consumption by 25%, and weight by 2-3% after a 15-hour intervention.”

Sufyan Hussain (UK) : Innodose – Device to reduce incidence of lipohypertrophy in long-term insulin users

“INNODOSE gamifies the injection process to reduce the incidence of lipohypertrophy in insulin-treated diabetes – with a co-design informed innovation of a novel insulin pen and pen-adaptor, drawing on collaboration between academics, clinicians, practitioners, engineers and designers at King’s College London, and with a focus on co-production with the end users.”

Muhammad Mujeeb-U-Rahman (US): CGM+ – Unleashing the Power of Next-Gen Monitoring for Diabetes

“Integrated Medical Sensors (IMS) has developed the world’s smallest, first fully-integrated (single chip) and first multi-sensor minimally invasive CGM, taking diabetes monitoring to the next level. It can monitor glucose using multiple independent sensors on the same device. In addition, it measures physiological parameters (e.g., tissue temperature) using the same device. Moreover, it can also measure multiple analytes (e.g., glucose and ketones) using a single device.”

Yuta Matsuda (US) : Genomelink – Innovative DNA Testing: A New Horizon in Type 1 Diabetes Diagnosis

“Misdiagnosis between T1D and T2D is common due to a lack of accessible diagnostic methods. Our new DNA test offers a more accessible and accurate tool for diagnosis. Unlike the fluctuating antibody levels, genetic markers associated with T1D do not change over a person’s lifespan, providing a stable diagnostic criterion.”